These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22320002)

  • 21. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics.
    Lodén M; Ungerth L; Serup J
    Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing Drug Safety in Children - The Role of Real-World Data.
    McMahon AW; Dal Pan G
    N Engl J Med; 2018 Jun; 378(23):2155-2157. PubMed ID: 29874532
    [No Abstract]   [Full Text] [Related]  

  • 23. The Safe Medical Devices Act.
    Williams MA
    South Hosp; 1992; 58(2):16-7. PubMed ID: 10118188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug safety: a contrarian's point of view.
    Cobert B
    Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392
    [No Abstract]   [Full Text] [Related]  

  • 25. The little agency that could (act with indifference to constitutional and statutory strictures).
    Noah L
    Cornell Law Rev; 2008 Jul; 93(5):901-26. PubMed ID: 18618963
    [No Abstract]   [Full Text] [Related]  

  • 26. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of firearms.
    Hemenway D
    N Engl J Med; 1998 Sep; 339(12):843-5. PubMed ID: 9738096
    [No Abstract]   [Full Text] [Related]  

  • 28. The Safe Medical Devices Act of 1990--FDA. Notice.
    Fed Regist; 1991 Apr; 56(66):14111-3. PubMed ID: 10111151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of cellular therapy in Australia.
    Trickett AE; Wall DM
    Pathology; 2011 Oct; 43(6):627-34. PubMed ID: 21897330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is New Zealand's regulation of nanomedical products adequate?
    Moore J
    J Law Med; 2011 Sep; 19(1):112-27. PubMed ID: 21988014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The new Sentinel Network--improving the evidence of medical-product safety.
    Platt R; Wilson M; Chan KA; Benner JS; Marchibroda J; McClellan M
    N Engl J Med; 2009 Aug; 361(7):645-7. PubMed ID: 19635947
    [No Abstract]   [Full Text] [Related]  

  • 33. The uncritical enthusiasts versus the uninformed sceptics: regulation of complementary and alternative medicines.
    Ellena KR
    J Law Med; 2005 Aug; 13(1):106-24. PubMed ID: 16117160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elements of causation in toxic tort litigation. Science and law must agree.
    Benjamin DM
    J Leg Med; 1993 Mar; 14(1):153-65. PubMed ID: 8463748
    [No Abstract]   [Full Text] [Related]  

  • 35. Post-marketing strategies for medicines.
    Breckenridge A
    Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pharmacologic surveillance and safety evaluation of new drugs].
    Reys LL
    Acta Med Port; 1991; 4(3):141-6. PubMed ID: 1950664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The emergence and popularisation of autologous somatic cellular therapies in Australia: therapeutic innovation or regulatory failure?
    McLean AK; Stewart C; Kerridge I
    J Law Med; 2014 Sep; 22(1):65-89. PubMed ID: 25341320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Probiotic Conundrum: Regulatory Confusion, Conflicting Studies, and Safety Concerns.
    Freedman SB; Schnadower D; Tarr PI
    JAMA; 2020 Mar; 323(9):823-824. PubMed ID: 32125410
    [No Abstract]   [Full Text] [Related]  

  • 39. The Food and Drug Administration's regulation of risk disclosure for implantable cardioverter defibrillators: has technology outpaced the Agency's regulatory framework?
    Basile EM; Lorell BH
    Food Drug Law J; 2006; 61(2):251-72. PubMed ID: 16903031
    [No Abstract]   [Full Text] [Related]  

  • 40. [Regulatory issues of biologically active supplements in Armenia].
    Gabrielian ES; Amroian EA; Zakarian AA; Osipian LL; Pogosian UG
    Vopr Pitan; 2003; 72(1):27-9. PubMed ID: 12664696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.